Cellectis Nom. diskutieren
Cellectis Nom.
WKN: A0MKPR / Name: Cellectis / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
Übersetzung fehlgeschlagen
Die Übersetzung durch Google Translate ist leider fehlgeschlagen.
kaufen
Position nach dem Rückgang der
Sehr interresant
ellectis is an international pharmaceutical company headquartered in Paris, France. It is focused on developing and offering immunotherapies based on gene-edited CAR-T cells (UCART). Unlike other companies in the CAR-T space, Cellectis offers allogeneic CAR-T cells, which allows it to produce an off-the-shelf alternative. The company plans to utilize its validated genome-editing technology to delete the T-cell receptor (TCR) from CAR-T cells. By deleting the TCR, the CAR-T cells are no longer able to detect "non-self", thus theoretically allowing T-cells from unrelated donors to be transplanted into recipients without the risk of graft-versus-host disease. This allogeneic cell production can be standardized and controlled, while autologous cells cannot, because they are sampled from individual patients. The company has a Phase I clinical trial using anti-CD19 CAR-T cells to treat ALL and CLL planned to start in Q2 2015.
Cellectis has two major big pharma partners - Servier Laboratories and Pfizer (NYSE:PFE), which provide clinical and regulatory expertise. Under the Pfizer collaboration announced in June 2014, Cellectis received $80M, funding for Pfizer-selected CAR-T targets, and up to $185M in milestones from eachcandidate Pfizer develops (~12 targets), and then finally, tiered royalties on any future sales. The cash and support from the Servier/Pfizer partnerships serve to buffer both financial and development risks moving forward. Cellectis currently has a market cap of $803.74M, $20.21M in cash, and a quarterly burn of $2M.
Zeitbombe
folgen
geldnutzer stimmt dem Sentiment von 'Buy' zu
geldnutzer stimmt am 03.01.2018 dem Buy-Gesamtsentiment mit dem Kursziel 26.6€ zu.
geldnutzer stimmt dem Sentiment von 'Buy' zu
geldnutzer stimmt am 28.04.2019 dem Buy-Gesamtsentiment mit dem Kursziel 27.7€ zu.
Neueste Beiträge
Lokrim in Capricor Therapeutics Inc diskutieren